Home
NICE Guidance
Conditions and diseases
Cancer
Metastases
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Technology appraisal guidance [TA414]
Published:
26 October 2016
Guidance
Tools and resources
Information for the public
Evidence
History
Do no do examples
Do no do examples for Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Title
Year published
Impact Level
No results could be found